Skip to main content

Table 1 Participant baseline demographics and clinical features

From: The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial

Variable

Control/dose escalation (n = 93)

Dose escalation/dose escalation (n = 90)

CrCL <30 ml/min (n = 14)

CrCL ≥30 to <60 ml/min (n = 31)

CrCL ≥60 ml/min (n = 48)

CrCL <30 ml/min (n = 10)

CrCL ≥30 to <60 ml/min (n = 40)

CrCL ≥60 ml/min (n = 40)

Age yearsa

68.2 (14.2)

66.6 (9.3)

54.8 (11.9)

66.8 (12.5)

64.6 (9.6)

52.5 (12.1)

Male, n (%)

7 (50%)

25 (80.6%)

46 (95.8)

9 (90%)

34 (85%)

39 (97.5)

Ethnicity, n (%)

 NZ European

6 (42.9%)

13 (41.9%)

20 (41.7%)

2 (20%)

21 (52.5%)

14 (35%)

 Maori

3 (21.4%)

10 (32.3%)

9 (18.8%)

3 (30.0%)

13 (32.5%)

13 (32.5%)

 Pacific Island

4 (28.6%)

6 (19.4%)

17 (35.4%)

5 (50%)

5 (12.5%)

9 (22.5%)

 Asian

1 (7.1)

2 (6.5%)

1 (2.1%)

0 (0%)

1 (2.5%)

4 (10.0%)

 Other

0 (0%)

0 (0%)

1 (2.1%)

0 (0%)

0 (0%)

0 (0%)

Duration of gout (years)

16.8 (14.8)

18.2 (14.7)

18.1 (11.9)

13.1 (11.2)

16.9 (11.2)

16.9 (11.2)

Baseline serum urate mg/dla

8.3 (1.5)

7.1 (1.6)

6.8 (1.5)

8.0 (1.6)

7.6 (1.6)

6.5 (1.3)

CrCL (ml/min)

19.8 (5.9)

44.3 (7.9)

82.4 (16.6

21.1 (6.7)

44.5 (8.1)

85.5 (17.7)

Body mass index (kg/m2)a

34.6 (7.2)

35.8 (8.3)

35.1 (7.5)

36.9 (8.4)

35.9 (8.4)

33.7 (6.8)

Baseline allopurinol dose mg/dayb

135.7 (100-250)

258.1 (150-400)

328.1 (200-600)

160.0 (100-300)

231.9 (100-600)

317.5 (150-600)

Allopurinol dose, n (%)

  ≤ 200 mg/day

13 (92.9%)

13 (41.9%)

5 (10.4%)

9 (90%)

25 (62.5%)

3 (7.5%)

  > 200–300 mg/day

1 (7.1%)

16 (51.6%)

33 (68.8%)

1 (10%)

13 (32.5%)

32 (80%)

  > 300 mg/day

0 (0%)

2 (6.5%)

10 (20.8%)

0 (0%)

2 (5%)

7 (7.8%)

Presence of palpable tophi, n (%)

10 (71.4%)

14 (45.2%)

22 (45.8%)

4 (40%)

13 (32.5%)

18 (45%)

Co-existing conditions, n (%)

 Obesityc

11 (78.6%)

23 (74.2%)

36 (75%)

8 (80%)

29 (72.5%)

27 (67.5%)

 Kidney stones

0 (0%)

1 (3.2%)

2 (4.2%)

1 (10%)

3 (7.5%)

1 (2.5%)

 Cardiovascular diseased

13 (92.9%)

14 (45.2%)

11 (22.9%)

5 (50%)

26 (65%)

10 (25%)

 Diabetes mellitus

8 (57.1%)

12 (38.7%)

13 (27.1%)

7 (70%)

18 (45%)

4 (10%)

 Hypertension

11 (78.6%)

29 (93.5%)

25 (52.1%)

9 (90%)

36 (90%)

22 (55%)

 Hyperlipidemia

12 (85.7%)

19 (61.3%)

27 (56.3%)

7 (70%)

22 (55%)

18 (45%)

Concurrent medications, n (%)

 Diuretic

13 (92.9)

19 (61.3%)

11 (22.9%)

7 (70%)

23 (57.5%)

8 (20.0%)

 Aspirin

11 (78.6%)

17 (54.8%)

13 (27.1%)

7 (70%)

23 (57.5%)

10 (25%)

Any anti-inflammatory prophylaxis

5 (35.7%)

15 (48.4%)

25 (52.1%)

4 (40%)

24 (60%)

23 (57.5%)

 Colchicine

2 (14.3%)

11 (25.5%)

22 (45.8%)

3 (30%)

13 (32.5%)

18 (45%)

 NSAID

0 (0%)

3 (9.7%)

6 (12.5%)

2 (20%)

4 (10%)

9 (22.5%)

 Prednisone

3 (21.4%)

8 (19.4%)

3 (6.3%)

1 (10%)

9 (22.5%)

2 (5%)

  1. CrCL creatinine clearance, NSAID non steroidal anti-inflammatory drug
  2. aMean (SD)
  3. bMean (range)
  4. cObesity defined as body mass index ≥30 kg/m2
  5. dCardiovascular disease defined as ischemic heart disease, heart failure or peripheral vascular disease
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us